The comparison of plasma fibronectin in term and preterm delivery: A cross-sectional, descriptive-analytical study


Background: Preterm delivery is one of the main causes of infant death. Therefore, prediction of preterm delivery may eliminate a large number of prenatal complications.

Objectives: The present study aimed to understand if preterm delivery can be predicted by assessing maternal plasma fibronectin concentration.

Materials and Methods: Serum samples from 105 pregnant women participating in this study were collected. The plasma fibronectin were measured at 24-28 wk of gestation and again at 32-36 wk of gestation. Unfortunately, only 65 of the 105 pregnant women, returned for the second sampling. The plasma fibronectin was analyzed using ELISA method and its concentration in term and preterm deliveries was compared. The delivery dates of all the women were also recorded.

Results: Out of 105 pregnant women, 28 delivered preterm (26.7%). The Plasma fibronectin concentrations in women with preterm delivery were higher than in those who delivered at term (p = 0.001). Accordingly, Plasma fibronectin concentrations were significantly higher in the second serum samples (p = 0.01). Plasma fibronectin concentrations was also higher in obese women and in those suffering from preeclampsia (p = 0.12) and gestational diabetes (p = 0.81).

Conclusion: Plasma fibronectin concentrations test could be used as an optional screening test for preterm delivery at 28 to 34 wk of gestation in pregnant women who prefer to avoid vaginal sampling.

Key words: Premature birth, Fibronectin, Maternal serum screening tests.

[1] Sultana Z, Maiti K, Aitken J, Morris J, Dedman L, Smith R. Oxidative stress, placental ageing-related pathologies and adverse pregnancy outcomes. Am J Reprod Immunol 2017; 77: doi: 10.1111/aji.12653.

[2] Forouhari S, Ghaemi SZ, Azadian M, Parsanezhad ME, Sarvestani E, Jokar A, et al. Predicting preterm delivery by measuring plasma fibronectin concentration. Int J Res Stud Biosci 2014; 2: 1–7.

[3] Howson CP, Kinney MV, McDougall L, Lawn JE. Born too soon: preterm birth matters. Reprod Health 2013; 10: S1.

[4] James DK, Steer PJ, Weiner CP, Gonik B, Robson SC. Highrisk pregnancy: management options. UK, Cambridge University Press; 2017.

[5] Halimi Asl AA, Safari S, Parvareshi Hamrah M. Epidemiology and related risk factors of preterm labor as an obstetrics emergency. Emerg 2017; 5: e3.

6] Khoshnood Shariati M, Karimi Z, Rezaienejad M, Basiri A, Torkestani F, Saleh Gargari S. Perinatal complications associated with preterm deliveries at 24 to 33 weeks and 6 days gestation (2011-2012): A hospital-based retrospective study. Iran J Reprod Med 2015; 13: 697–702.

[7] Purisch SE, Gyamfi-Bannerman C. Epidemiology of preterm birth. Seminars in perinatology 2017; 41: 387–391. [8] Martin RJ, Fanaroff AA, Walsh MC. Fanaroff and Martin’s Neonatal-Perinatal Medicine E-Book: Diseases of the Fetus and Infant: Elsevier Health Sciences; 2010.

[9] van der Krogt L, Ridout AE, Seed PT, Shennan AH. Placental inflammation and its relationship to cervicovaginal fetal fibronectin in preterm birth. Eur J Obstet Gynecol Reprod Biol 2017; 214: 173–177.

[10] McLaren JS, Hezelgrave NL, Ayubi H, Seed PT, Shennan AH. Prediction of spontaneous preterm birth using quantitative fetal fibronectin after recent sexual intercourse. Am J Obstet Gynecol 2015; 212: 89. e1–e5.

[11] Severens-Rijvers CAH, Al-Nasiry S, Ghossein-Doha C, Marzano S, Ten Cate H, Winkens B, et al. Circulating fibronectin and plasminogen activator inhibitor-2 levels as possible predictors of recurrent placental syndrome: An exploratory study. Gynecol Obstet Invest 2017; 82: 355–360.

[12] Macones GA. Fetal fibronectin testing in threatened preterm labor: time to stop. Am J Obstet Gynecol 2016; 215: 405.

[13] Zygmunt M, Lang U, Katz N, Künzel W. Maternal plasma fibronectin: a predictor of preterm delivery. Eur J Obstet Gynecol Reprod Biol 1997; 72: 121–126.

[14] Ekaidem IS, Bolarin DM, Udoh AE, Etuk SJ, Udiong CE. Plasma fibronectin concentration in obese/overweight pregnant women: a possible risk factor for preeclampsia. Indian J Clin Biochem 2011; 26: 187–192.

[15] Dane C, Buyukasik H, Dane B, Yayla M. Maternal plasma fibronectin and advanced oxidative protein products for the prediction of preeclampsia in high risk pregnancies: a prospective cohort study. Fetal Diagn Ther 2009; 26: 189–194.

[16] Rasanen J, Quinn MJ, Laurie A, Bean E, Roberts CT Jr, Nagalla SR, et al. Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia. Am J Obstet Gynecol 2015; 212: 82. e1– e9.

[17] Parker MG, Ouyang F, Pearson C, Gillman MW, Belfort MB, Hong X, et al. Prepregnancy body mass index and risk of preterm birth: association heterogeneity by preterm subgroups. BMC Pregnancy Childbirth 2014; 14: 153.

[18] Kim SS, Mendola P, Zhu Y, Hwang BS, Grantz KL. Spontaneous and indicated preterm delivery risk is increased among overweight and obese women without prepregnancy chronic disease. BJOG 2017; 124: 1708– 1716.

[19] Bahrami Taghanaki H, Hashemian M, Lotfalizadeh M, Noras M. [The relationship between Body Mass Index (BMI) and birth weight and some pregnancy outcomes.] Iran J Obstet Gynecol Infertil 2016; 19: 1–8. (in Persian)

[20] Ahmadi Taheri S, Ramazani Ahmadi AH, Javadi M, Barikani A. [Comparison of dietary patterns during pregnancy in the mothers of the infants with low birth weight and normal weight]. Iran J Obstet Gynecol Infertil 2018; 21: 80–89. (in Persian)

[21] Salem Z, Ebrahimi F, Aminzadeh F, Asadolahi Z. The prevalence of malnutrition and its association with pregnancy outcome among pregnant women in Rafsanjan, Iran, in 2016. J Occup Health Epidemiol 2017; 6: 106– 113.

[22] Chen X, Zhao D, Mao X, Xia Y, Baker PN, Zhang H. Maternal dietary patterns and pregnancy outcome. Nutrients 2016; 8: 351.

[23] Shoja M, Shoja E, Shoja E, Gharaei M. Prevalence and affecting factors on preterm birth in pregnant women Referred to Bentolhoda hospital-Bojnurd. J North Khorasan Univ Med Sci 2016; 7: 855–863.